Attorney Docket No. PB60516

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Johnson et al.

April 21, 2008

Serial No.:

10/572,671

Group Art Unit No.: 1624

Filed:

March 20, 2006

Examiner: E. B. Bernhardt

For:

PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE

TREATMENT OF CNS DISORDERS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the **§180.00** fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Serial No.: 10/572,671 Group Art Unit No.: 1624

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

Kathryn (Sieburth Attorney for Applicants Registration No. 40,072

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5023 Facsimile (610) 270-5090